Tell us exactly what Todd means when he reports that Generex is ‘moving forward on all fronts’.

I give you an otc poster-child as a contrasting case in point: Todos Medical recently bottomed out around .02. They continue to inform investors about efforts to create revenue streams, some of them covid related. Volume over the last three trading sessions has increased from 9m per day to nearly three times that, with a share price now over .08. Optimism prevails because they have described where revenue will likely be coming from over the next quarter.

That is what we’re missing with GNBT.